BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)

BrainsWay’s strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation ...
BioWorld

Neuromodulation for MDD heads home

For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.
Seeking Alpha

FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder

TITUSVILLE, N.J., Nov. 6, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved CAPLYTA ® (lumateperone) as an adjunctive therapy ...
EurekAlert!

New study links lipid-related metabolites to depression risk and protection

Metabolic dysregulation has been implicated in major depressive disorder (MDD), but the causal relationship between plasma ...
The American Journal of Managed Care

Effects of Adjunctive Cariprazine Formulary Restrictions in Major Depressive Disorder

Patients who experienced a formulary-related rejection of cariprazine for adjunctive treatment of major depressive disorder had significantly higher hospitalization rates than those with approved ...